Insider Trading Disclosure
Laurus Labs Promoters Sell 20.7 Lakh Shares
Laurus Labs clarified that promoters Dr. Satyanarayana Chava and V. V. Ravi Kumar sold a total of 20.7 lakh equity shares on November 11 and 12, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.



Laurus Labs Ltd (LAURUSLABS) is currently trading at 2,350.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Laurus Labs is a science-led, vertically integrated pharmaceutical and biotechnology manufacturer spanning affordable medicines, APIs, CDMO services, fermentation and specialized ingredients. Its principal strengths are complex chemistry, large-scale manufacturing, global regulatory compliance and established relationships with pharmaceutical partners across human health, animal health and emerging therapeutic modalities. Laurus Labs delivered record Q2 FY27 revenue of INR2,206 crores, with EBITDA rising to INR762 crores and a 34.5% margin. H1 revenue grew 31% to INR4,233 crores, while H1 PAT reached INR809 crores, demonstrating that operational leverage and favorable business mix are translating substantial capacity investments into improved profitability. The most significant strategic shift is toward complex, integrated CDMO capabilities. Laurus Labs now combines more than 9,000 kiloliters of small-molecule API reactor volume with commercial-scale peptide synthesis, purification and isolation infrastructure, while building capabilities in oligonucleotides, ADCs, gene therapy and fermentation. CDMO sales grew 86% year-on-year to INR875 crores in Q2, supported by late-stage programs and commercial API supplies. Management expects continued visibility from diversified programs, with no significant customer concentration or anticipated near-term destocking, although commercial peptide revenues are expected only around the FY29 timeframe. Laurus Labs is pursuing an ambitious investment cycle while maintaining financial discipline. H1 capex was INR864 crores, net debt was INR2,466 crores, and debt-to-EBITDA improved to approximately 1.02 times. However, free cash flow remains constrained by growth capex, inventory absorption and investments in new technology platforms.
Over the past 52 weeks, Laurus Labs Ltd has traded between a low of ₹913.35 and a high of ₹2,481.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Laurus Labs Ltd has a market capitalization of approximately 1,26,433.06. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Laurus Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 94.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,26,433.06 Cr, Laurus Labs Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Laurus Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Laurus Labs Ltd is 94.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Laurus Labs reported Q2 FY27 income from operations of Rs 2,206 crore, which management said was its highest quarterly level since inception. H1 FY27 income from operations was Rs 4,233 crore, up 31% year on year.
Laurus has disclosed a little over 16 KL of SPPS synthesizer capacity. It has not disclosed its LPPS capacity or the total investment in the peptide facility.
Laurus Labs Limited reported revenue from operations of ₹2,206 crore in Q2 FY27. The company said this was its highest quarterly revenue since inception and represented 33% year-on-year growth.
Laurus Labs generated ₹6,813 crore in revenue in FY2026.

View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
6
Bullish
5
Bearish
11
Neutral
6
Bullish
29
Bearish
8
Neutral
0
Bullish
24
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,26,973 Cr
Low Risk
95.2
39.0
7.7
20.9
2,481.50
913.35
Sales CAGR
Profit CAGR
ROE
ROCE